Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Receivables - Accured (2024 - 2025)

SAB Biotherapeutics' Receivables - Accured history spans 2 years, with the latest figure at $900000.0 for Q4 2025.

  • For Q4 2025, Receivables - Accured rose 1537.7% year-over-year to $900000.0; the TTM value through Dec 2025 reached $900000.0, up 1537.7%, while the annual FY2025 figure was $900000.0, 1537.7% up from the prior year.
  • Receivables - Accured reached $900000.0 in Q4 2025 per SABSW's latest filing, up from $560000.0 in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $900000.0 in Q4 2025 to a low of $21386.0 in Q1 2025.